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Abstract. Glypicans are a family of glycosylphosphati- 
dylinositol (GPI)-anchored cell surface heparan sulfate 
proteoglycans (HSPGs). The glypican family, which 
currently includes glypican, the developmentally regu- 
lated rat intestinal transcript OCI-5, and cerebroglycan, 
is characterized by a similar core protein size and al- 
most complete conservation of cysteine residues. By 
RT-PCR using degenerate oligonucleotide primers 
based on the sequence homologies, we isolated mouse 
cDNA encoding a novel member of the glypican family 
as well as mouse homologues of glypican and OCI-5. 
The novel molecule, named K-glypican, has a predicted 
molecular mass of 57.5 kD and potential attachment 
sites for heparan sulfate chains and a GPI anchor in its 
COOH-terminal region, like other members of the 
glypican family. Transfection of an epitope-tagged 
full-length K-glypican cDNA into MDCK cells demon- 
strated that K-glypican is indeed expressed as a GPI- 
anchored HSPG. Northern blot analyses with K-glypi- 
can, glypican, and OCI-5 probes demonstrated that 
K-gtypican mRNA is highly expressed in the mouse 
kidney and developing brain, and that these three mol- 
ecules show remarkable patterns of cell type- and de- 
velopmental stage-specific expression. In situ hybrid- 
ization revealed that the major sites of K-glypican 
expression in developing embryo are tubular epithelial 
cells in the kidney and proliferating neuroepithelial 
cells in the brain. These results indicate that K-glypican 
is a novel GPI-anchored HSPG involved in embryonic 
development. 
H 
EPARAN sulfate proteoglycans (HSPGs) 1  are thought 
to be involved in a variety of biochemical and bio- 
logical processes  such  as cell adhesion, modula- 
tion  of growth  factor  activities,  blood  coagulation,  and 
lipid metabolism (reviewed in Ruoslahti, 1989; Jackson et 
al., 1991; Ruoslahti and Yamaguchi, 1991; Bernfield et al., 
1992; Yanagishita and Hascall, 1992). HSPGs occur at the 
cell surface and in the extracellular matrix. Four types of 
cell  surface  HSPGs  have  been  identified by  molecular 
cloning (Bernfield et  al.,  1992; David,  1993).  Syndecans 
are a  family of transmembrane HSPGs with highly con- 
served cytoplasmic domains (Bernfield et al., 1992). Beta- 
glycan, also known as the type III TGF-13 receptor,  is a 
transmembrane proteoglycan carrying both heparan and 
chondroitin  sulfate  chains  (L6pez-Casillas  et  al.,  1991; 
Wang et al., 1991). A subtype of CD44 has been shown to 
exist as an HSPG in some epithelial cells (Brown et al., 
1991). Finally, glypican and glypican-like molecules form a 
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family of cell surface HSPGs  that  are  anchored  to  cell 
membranes by a glycosylphosphatidylinositol (GPI) link- 
age. 
Glypican was first characterized and molecularly cloned 
in  human  fibroblasts  (Lories  et  al.,  1987; David  et  al., 
1990). In fibroblasts, glypican has a 62-kD core protein to 
which three to  four heparan sulfate chains are  attached 
(David  et  al.,  1990).  Rat  glypican has  been  cloned  and 
shown to be highly homologous to human glypican (Kar- 
thikeyan et al.,  1992).  Filmus et al.  (1988)  have isolated 
cDNA for a developmentally regulated transcript (OCI-5) 
in  rat  intestine, which was  later found to be  related  to 
glypican. Recently, Stipp et al.  (1994)  have reported yet 
another glypican-like HSPG,  named cerebroglycan; this 
proteoglycan is  specifically expressed  in  the  developing 
nervous system. Although the primary structures of glypi- 
can, OCI-5, and cerebroglycan are conserved at the rela- 
tively low levels of 20-40%, the numbers and positions of 
cysteine residues are almost completely conserved (Kar- 
thikeyan et al.,  1992; Stipp  et al.,  1994).  Like the trans- 
membrane HSPGs, GPI-anchored HSPGs have been im- 
plicated in cell adhesion and migration (Drake et al., 1992; 
Campos et  al.,  1993; Carey et  al.,  1993),  modulation of 
growth factor actions (Brunner et al.,  1994; Metz et al., 
1994), anticoagulation (Mertens et al., 1992), and lipopro- 
tein metabolism (Chajek-Shaul et al.,  1989; Misra et al., 
1994). It has been shown that a single cell type often ex- 
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transmembrane and GPI-anchored types (see e.g., Lories 
et al., 1992; Mertens et al., 1992). 
Proteins anchored in membranes by GPI are widely dis- 
tributed.  Examples  include  Thy-1, N-CAM,  T-cadherin, 
and the receptor for ciliary neurotrophic factor (reviewed 
in  Cross, 1990; Rodriguez-Boulan and Powell, 1992).  Al- 
though a general physiological function directly attribut- 
able to GPI-anchor has not been identified, the biochemi- 
cal and metabolic differences between GPI-anchored and 
transmembrane  proteins  have  been  well  characterized. 
First,  GPI-anchored proteins  use  shedding,  endocytotic, 
and  degradation  pathways  distinct  from  those  of trans- 
membrane proteins. Second, GPI-anchored proteins tend 
to exhibit lateral mobility in cell membranes that is much 
higher than that of transmembrane proteins (Cross, 1990). 
Third, GPI-anchored proteins are usually targeted to the 
apical surface in polarized epithelial cells (Lisanti et al., 
1988).  This body of information collectively suggests that 
the GPI linkage may render the glypican family of HSPGs 
functionally unique  compared with  syndecans and  other 
transmembrane HSPGs. It is possible that different core 
proteins are attached with heparan sulfates that have dis- 
tinct binding specificities for ligands.  Glypicans, because 
of the GPI-anchor, may be distributed differently on the 
cell surface compared to transmembrane HSPGs, thereby 
playing unique biological roles in tissues. 
The  unique  pattern  of structural  conservation  of the 
glypican family of HSPGs has allowed us to search for ad- 
ditional unknown glypican-like molecules. Molecular clon- 
ing and subsequent expression studies of such novel mole- 
cules provide clues to understand functional roles of this 
family of proteoglycans. To isolate cDNAs encoding novel 
members  of  the  glypican  family,  we  have  employed  a 
PCR-based  approach. Here, we report the identification 
of a novel member of the glypican family. This molecule, 
named  K-glypican,  was  isolated  from  a  mouse  kidney 
cDNA library and shown to be expressed as a GPI-anchored 
HSPG in transfected MDCK cells. The expression pattern 
of K-glypican in mouse embryos suggests that this mole- 
cule may be  involved in  the  development of kidney tu- 
bules and of the central nervous system. 
Materials and Methods 
Materials 
SuperScript  Preamplification System and the 0.24-9.5-kb  RNA Ladder 
were purchased from GIBCO BRL (Gaithersburg, MD). Taq DNA poly- 
merasc, the random priming DNA labeling kit, phosphatidylinositol-spe- 
cific phospholipase C  (PI-PLC)  from Bacillus cereus, Proteinase K, the 
digoxigenin RNA labeling mixture, alkaline phosphatase conjugated anti- 
digoxigenin Fab fragments, and restriction enzymes were obtained from 
Boehringer Mannheim Corp. (Indianapolis, IN). The enzymes for Erase- 
a-Base system, T7 and T3 RNA polymerases, and pGEM-T vector were 
purchased from Promega Corp.  (Madison, WI).  A  mouse kidney hgt10 
cDNA library was obtained from Clontech (Palo Alto, CA). Sequenase 
version 2.0 kit was purchased from United States Biochemical (Cleveland, 
OH).  Radioisotopes and  GeneScreen Plus nylon membranes were pur- 
chased from DuPont NEN (Boston, MA). Precast gels for SDS-PAGE 
were obtained from Novex (San Diego, CA). The ECL Western blotting 
detection  reagents  were  obtained  from  Amersham  Corp.  (Arlington 
Heights, IL).  Culture supernatants of anti-c-myc hybridoma 9E10 were 
the generous gift of Dr. Minoru Fukuda (La Jolla Cancer Research Foun- 
dation, La Jolla, CA). The expression vector, pSRc~-neo,  was kindly pro- 
vided by Dr. Norio Ishida (National Institute of Bioscience and Human 
Technology, Tsukuba, Japan). 
Cell Culture 
MDCK  cells  were  obtained  from  American  Type  Culture  Collection 
(Rockville, MD). A  mouse thymic epithelial cell line 2RO1.1 was kindly 
provided by Dr. Hiroshi Kosaka (RIKEN, Tsukuba, Japan).  Mouse en- 
dothelial cell lines, sEnd.l, tEnd.l, eEnd.2, and bEnd.4, originally estab- 
lished by Dr. R. Lindsay Williams (EMBL, Heidelberg, Germany), were 
provided by Dr. Minoru Fukuda (La Jolla Cancer Research Foundation, 
La Jolla, CA). 
RT-PCR 
Nine degenerate oligonucleotide primers were designed based on three 
conserved cysteine-rich regions in the published amino acid sequences of 
human glypican (David et al., 1990)  and rat OCI-5 (Filmus et al,  1988): 
5'-primers: Primer 1, 5'-TGC TGC A/TCA/C AGA/C A/GAG ATG GA- 
3':  Primer  2,  5'-TAC  TGC/T  G/TCT  C/TAG  TGC  CA/T  G  GG-3'; 
Primer 5,  5'-CCC A/CAG  GGI  C/TA/CI  ACI TGC TG-3';  Primer 6, 
5'-CAI G/CTI A/CA/CI C/TTI A/GGI A/CA/CI GAI TG-3'; 3'-primers: 
Primer 3, 5'-GGC TGC AG/CA G/TG/TG/T A/TG/CC CTG GG/CA-3'; 
Primer 4, 5'-CCG TTC CAG CAG/C A/CGG G/TC/TA/G TC-3': Primer 
7,  5'-TCI AG/TI TCG/T A/GCI A/TG/CI C/TC/TI GCA/C AG/TA/G 
CA-3'; Primer 8, 5'-A/TG/TI G/TA/CI A/TG/TI CCA/G TTC CAG CA- 
3';  Primer 9,  5'-CCC IGG  CAA/G TA/GA/G  GA/CA/G  CAG  TA-3'. 
The first strand cDNA for amplification was synthesized from total RNA 
with  Primer  8  by  SuperScript  reverse  transcriptase  using SuperScript 
Preamplification kit (GIBCO BRL). PCR was carried out as follows: 35 
cycles consisting of the reactions; denaturing, 94°C, 50 s; annealing, 52°C, 
1 min; extension, 72°C, 2 min. The PCR products were ligated into a TA- 
overhanging vector prepared  from pBluescript  IIKS+  using Taq DNA 
polymerase (Marchuk et al., 1991)  or pGEM-T (Promega). The ligation 
mixtures were introduced into Escherichia coli strain TOP10F'  (Invitro- 
gen, San  Diego,  CA)  by electroporation,  t00  clones containing inserts 
were transferred to replica plates to carry out colony hybridization. Plas- 
mids were isolated from 19 randomly selected transformants. Sequencing 
of these plasmids revealed that  one of the clones, M2.  has a  deduced 
amino acid sequence similar to but distinct from those of glypican and 
known glypican-like molecules. Three other clones, B1, B2, and M6, were 
shown to contain sequences indicative of mouse homologues of glypican 
(B1)  and  OCI-5  (B2  and M6),  respectively (see Results).  To  avoid  re- 
peated sequencing, the remaining clones were examined by colony hybrid- 
ization with clones M2, B1, and B2 as probes (Sambrook  et  al., 1989). 
Clones that did not hybridize with any one of these probes were fur 
ther characterized  by sequencing. DNA probes were radiolabeled  with 
[a-3ZP]dCTP  by the random priming method (Feinberg and Vogelstein, 
1983). The nucleotide sequences of the clones were analyzed using Seque- 
nase kit. 
cDNA Cloning 
A  cDNA  library  from  mouse  kidney  (Clontech)  was  screened  using 
32p-labeled  0A-kb  EcoRI/HindIII  fragment  of  clone  M2  as  a  probe. 
Eleven positive clones were obtained from 1 ×  106 clones of the library by 
sequential  plaque  hybridization  (Sambrook  et  al.,  1989).  The  phage 
DNAs of the positive clones were  prepared  according to  Helms et  al. 
(1985)  and subjected to restriction analyses. Three clones carrying the 
longest cDNA inserts, XMK6, hMK7, and hMKll, were subcloned into 
pBluescript IIKS+ (Stratagene, San Diego, CA) and sequenced by prepar- 
ing a set of deletion mutants and by using synthetic oligonucleotide prim- 
ers. The DNA and amino acid sequences were analyzed with the program, 
DNA Strider  TM 1.2. The BLAST system was used for homology searches 
of protein databases. 
Construction of the Expression Vectors of 
Epitope-tagged Proteins 
Tagging with human c-myc 9E10 epitope (Evan et al., 1985) was designed 
at two sites in the putative glypican-like cDNA. The nucleotide sequence 
corresponding to the amino acid sequence of the epitope, EQKLISEEDL, 
was  introduced  into  the  cDNA  by  PCR.  The  PCR  primers;  S-myc, 
5'-AGA GCT CGA ACA AAA GCT GAT "['TC TGA AGA AGA CCT 
CAA GTC GAA AAG TTG CTC-3'  and  K-myc, 5'-TGG TAC CTC 
AAG TCT TCT TCA GAA ATC AGC TIT TGT TCG Cq'T TTG CCT 
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minal Sac I and COOH-terminal Kpn I sites of the cDNA, respectively 
(see  Fig.  4  A).  Three  restriction  fragments of hMK6,  namely 0.8-kbp 
EcoRI, 2.4-kbp EcoRI, and 1.9-kbp BamHI/EcoRI fragments, were sub- 
cloned into pBluescript IIKS to generate subclones pEco6b, pEco6a, and 
pBEI9,  respectively.  The  cDNA  fragment  containing  the  epitope  se- 
quence at the Sac I  site was amplified by PCR with the S-myc and SK 
primers using the 0.3-kbp Sac I  fragment of pEco6b,  and the fragment 
containing the epitope  sequence at the Kpn I  site with the K-myc and 
Primer 2 using the 1.0-kbp Kpn I fragment of pEco6a. The PCR products 
were subcloned into pGEM-T. The subclones, pSmyc and pKmyc, were 
sequenced to confirm the introduced and amplified sequences. A BamHl/ 
Kpn [ portion of pBE19 was replaced with a 0.4-kbp BamHI/Kpn I frag- 
ment from pKmyc. An EcoRI/Kpn I portion of the replaced plasmid was 
then replaced with a 0.4-kbp EcoRI/Kpn I fragment from hMK7 to gener- 
ate pBE08Kmyc. A 0.8-kbp BamHI/EcoRI fragment of pBE08Kmyc was 
ligated into pcDNAl/Amp (Invitrogen) together with a  1.2-kbp BamH1 
fragment from hMK6 to construct the expression vector pKGPKmyc. A 
EcoRI/Nco I fragment from hMK6 was subcloned into HinclI/EcoRI sites 
of pUC18 with conversion of Nco I site into blunt end. The EcoRI/Sac I 
portion was replaced with a 0.3-kbp EcoRI/Sac I fragment from pSmyc. A 
0.3-kbp EcoRI/HindlII fragment from the replaced plasmid and a 1.4-kbp 
EcoRI fragment of hMK7 were cloned into EcoRI/HindlII sites of pcDNAI/ 
Amp to construct pKGPSmyc. A  1.8-kbp Pst I fragment of pKGPSmyc 
was subcloned into pBluescript IIKS, and a PvulI/Sma I fragment of the 
subclone was ligated into pCEP-4 (Invitrogen). A  Xba I fragment from 
the resulting plasmid was inserted into the Spe I site of pSRet-neo to con- 
struct pSKGPSmyc. The structures of all constructs were confirmed by re- 
striction analysis and sequencing. 
Transfection 
MDCK cells were transfected by the calcium phosphate method with the 
following expression constructs: pKGPKmyc for the Kmyc-tagged protein 
expression, pSKGPSmyc for  the  Smyc-tagged protein  expression, and 
pSRa-neo for control, pKGPKmyc was cotransfected with pSRtx-neo (10:1 
molar ratio), since the vector does not contain selective markers. During 
the transfection, sodium butyrate was added to the culture at the concen- 
tration of 10 mM (Gorman and Howard, 1983), The transfectants were se- 
lected with G418 (500 ixg/ml), and colonies of resistant cells were isolated 
with cloning rings. The G418-resistant clones were analyzed by Western 
blotting to determine the expression of the epitope-tagged proteins. Two 
clones, K1B4 and $2A3 expressing Kmyc-tagged and Smyc-tagged pro- 
teins, respectively, were selected for further experiments. 
Enzyme Treatments 
Fractions enriched for proteoglycans ("PG fraction") were prepared from 
culture supernatants of the transfectants by DEAE ion-exchange column 
chromatography as described previously (Yamada et al., 1994).  The PG 
fractions were  concentrated  by  Centricon-30  (Amicon  Corp.,  Beverly, 
CA)  and then treated  with a  mixture of heparinases I  and  III  (Sigma 
Chemical Co., St. Louis, MO) or chondroitinase ABC (Seikagaku Amer- 
ica, Rockville, MD) in 100 mM sodium acetate, pH 7.0, containing 1 mM 
calcium acetate, 1 mM PMSF, 10 mM N-ethylmaleimide, 7.2 ~M pepstatin 
A, and 10 ~M leupepfin. 
For  the preparation  of cell  extracts, cultures were  treated  overnight 
with  the  medium  containing  10  mM  sodium  butyrate  (Gorman  and 
Howard, 1983), and then the cells were harvested by scraping in 50 mM 
Tris/HCl, pH 7.6,  containing 150  mM NaC1, 2  mM EDTA, and  1 mM 
PMSF after washing the cell monolayers three times with PBS. The cells 
were collected by centrifugation and suspended in 600 ~zl of 50 mM Tris/ 
HC1, pH 7.6, containing 1 mM PMSF, 10 mM N-ethylmaleimide, 7.2 ~tM 
pepstatin A, and 10 tzM leupeptin. The cell suspensions were divided into 
two microtubes and incubated with or without 200 mU of PI-PLC at 37°C 
for 1 h. After the incubation, 200 I-d of 5 M NaC1 was added to the reaction 
mixture and incubated on ice for 15 min. The fraction released by PI-PLC 
was  obtained  as  supernatant by  centrifugation.  Residual  cell  fractions 
were  solubilized in 500 l-d of 20 mM Tris/HC1, pH 8.0, containing 300 mM 
NaCI, 2 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 1 mM 
PMSF, 10 mM N-ethylmaleimide, 7.2 p~M pepstatin A, and 10 ~M leupep- 
tin. An aliquot from each fraction was precipitated with acetone and then 
resolved in SDS-PAGE. Epitope-tagged proteins were detected with anti- 
c-myc 9E10 mAb (Evan et al., 1985)  by Western blotting using the ECL 
Western blotting detection kit (Amersham). 
Northern Blotting 
Total  RNAs were isolated from cell lines and tissues by the guanidine 
isothiocyanate method (Chirgwin et al., 1979).  Aliquots of total RNAs (10 
p,g) denatured by DMSO and glyoxal were electrophoresed in 1.0% agar- 
ose gels, transferred to nylon membrane filters (GeneScreen Plus, DuPont 
NEN), and hybridized with 32p-labeled cDNA probes. Probes for glypi- 
can, OCI-5, and K-glypican were prepared by PCR with Primers 5 and 9 
using clone B1, B2, and hMK6, respectively, and then radiolabeled by the 
random priming method as described above. The filter was reprobed with 
human  13-actin  cDNA  to  ensure  that  a  similar  amount  of RNA  was 
present in each lane. 
In Situ Hybridization 
A  1.4-kbp EcoRI fragment from hMK7 was subcloned into pBluescript 
IIKS+. The resulting subclone, pEco7a, was linearized by digestion with 
Hind III (for the synthesis of antisense probes) or Pst I (for the synthesis 
of sense probes). RNA probes were synthesized with T3 or T7 RNA poly- 
merase (Promega) using a digoxigenin RNA labeling mixture (Boehringer 
Mannheim). 
Paraformaldehyde-fixed paraffin sections of mouse embryos (Novagen, 
Inc., Madison, WI) were first treated with xylene to remove paraffin. The 
procedures for hybridization, washing, and development were according 
to Ohtani et  al. (1992)  with minor modifications. Briefly, sections were 
treated with Proteinase K, fixed with 4% paraformaldehyde, and then de- 
hydrated and delipidated by treatment with ethanol and chloroform. Af- 
ter rehydration with 2x SSC, hybridization was performed at 50°C for 16 h 
with alkaline-treated  RNA probes.  Immunological detection of hybrid- 
ized probes  was performed  with  alkaline  phosphatase-conjugated anti- 
digoxigenin antibodies (Boehringer Mannheim) in the presence of polyvi- 
nyl alcohol (De Block and Debrouwer, 1993). Anatomical and histological 
structures were identified on the basis of an atlas of developing mouse em- 
bryo  (Kaufman, 1992).  For the identification of neuroanatomical struc- 
tures, we  also consulted an atlas of developing rat  brain (Altman and 
Bayer, 1995). 
Results 
PCR-based Cloning of cDNAs Encoding 
Glypican-like Molecules 
To  isolate  cDNAs  encoding  unknown  members  of  the 
glypican family proteoglycans, we designed nine degener- 
ate PCR primers based on the conservation between the 
amino  acid  sequences  of human  glypican  (David  et  al., 
1990)  and rat OCI-5 (Filmus et al.,  1988).  These primers 
were tested in various combinations for amplification of 
DNA fragments that have sizes expected for glypican-like 
molecules.  We  applied  this  PCR-based  search  of novel 
glypican-like molecules to mRNA from adult mouse kid- 
ney, brain, spleen, and ovary. We found that 0.5-0.6-kbp 
bands  were  reproducibly  amplified  from  mouse  kidney 
mRNA  using  Primer 5  and  9.  The  amplified PCR  frag- 
ments were subcloned, and 19 randomly selected subclones 
were analyzed by sequencing. Among the sequenced sub- 
clones, B1 and B2 were shown to have deduced amino acid 
sequences  ~90%  homologous to  glypican (David  et  al., 
1990;  Karthikeyan et al., 1992) and OCI-5 (Filmus et al., 
1988), respectively (Fig. 1 B). Such high levels of sequence 
homology indicate that clone B1 represents mouse glypi- 
can, and clone B2 mouse OCI-5. On the other hand, one of 
the sequenced clones, M2, was shown to have a sequence 
similar to, but clearly distinct from glypican, OCI-5, and 
cerebroglycan. When these sequences are aligned, it was 
noted that cysteine residues as well as several other amino 
acid residues are conserved between M2 and other mem- 
bers of the glypican family (Fig.  1 A). In contrast to the 
high  levels  of  interspecies  sequence  identities  found  in 
Watanabe et al. K-Glypican, A Novel GPl-anchored HSPG  1209 glypican  and  OCI-5,  identities  between  M2  and  other 
members of the family are much lower. For instance, M2 
shows 45, 24, and 42% sequence identities with the corre- 
sponding regions  of rat  glypican, OCI-5, and cerebrogly- 
can,  respectively  (Fig.  1  B).  These  results  strongly  sug- 
gested  that  M2  represents  a  partial  cDNA  of  a  novel 
glypican-like molecule. 
Predicted Primary Structure of a Novel Glypican-like 
Molecule (K-Glypican) 
To isolate  the  entire  coding region of the putative  novel 
glypican-like molecule, a mouse kidney cDNA library was 
screened by using an EcoRI/HindlII fragment of clone M2 
as a probe. Among 11 clones isolated after three rounds of 
plaque  hybridization,  a  clone, hMK6,  was shown to con- 
tain an insert covering the entire open reading frame. The 
nucleotide  and  deduced  amino  acid  sequences  of hMK6 
are shown in Fig. 2. An open reading frame begins at nu- 
cleotide 470, ACC47°ATGG, which is typical of a consen- 
A 
M2  SQEMESKYSLQSKDDFKTWSEQCNHLQAIFASRYKKFDEFFKELLENAEKSLNDMFVKTYGHLY 
hGLP  TSEMEENLANRSHAELETALRDSSRVLQAMLATQLRSFDDHFQHLLNDSERTLQATFPGAFGELY 
rGLP  TSEMEENLANHSRMELETALHDSSKALQATLATQLHGIDDHFQRLLNDSERTLQDAFPGAFGDLY 
B1  TSEME~NLANHSRMELESALHDSSRALQATLATQLHGIDDHFQRLLND~ERTLQGAFPGAFGDLY 
rOCI  SRKMEEKYQLTARLNMEQLLQSASMELKFLIIQNAAVFQEAFEIWRHAKNYTNAMFKNNYPSLT 
B2  SRKMEEKYQLTARLNMEQLLQSASMELKFLIIQNAAVFQEAFEI'WRHAKNYTNAMFKNNYPSLT 
rCRB  SSETEQKLIRDAEVTFRGLVEDSGSFLIHTLAARHRKFNEFFREMLSISQHSLAQLFSHSYGRLY 
M2  MQNSELFKDLFVELKRYYVAGNVNLEEMLNDFWARLLEEMFRLVNSQYH-  FTDEYLE---CVS 
hGLP  TQNAKAFRDLYSELRLYYRGANLHLEETLAEFWARLLEELFKQLHPQLL---LPDDYLD---CLG 
rGLP  TQNTRAFRDLYAELRLYYRGANLHLEETLAEFWARLLERLFKQLHPQLL---LPDDYLD---CLG 
BI  TQNTRAFRDLYAELRLYYRGANLHLEETLAEFWARLLERLFKQLHPQLL  ....  PDDYLD-  -CLG 
rOCI  PQAFEFVGEFFTDVSLYILGSDINVDDMVNE---  LFDSLFPVIYTQMMNPGLPESVLDINECLR 
B2  PQLFEFVGEFFTDVSLYILGSDINVDHMVNE---  LFDSLFPVIYTQMMNPGLPESVLDINECLR 
rCRB  SQHAVIFNSLFSGLRDYYEKSGEGLDDTLADFWAQLLERAFPLLHPQYS---FPPDFLL---CLT 
M2  KYTEQ  ....  LKPFGDVPEKLKLQVTRAFVAARTFAQGLAVARDVVSKVSVVNPTAQCTHALLKMI 
hGLP  KQAEA--  LRPFGEAFRELRLRATRAFVAARSFVQGLGVASDVVRKVAQVPLGPECSRAVMKLV 
rGLP  KQAEA---  LRPFGDAPRELRLRATRAFVAARSFVQGLGVASDVVRKVAQVPLAPECSRAVMKLV 
B1  KQAEA  ....  LRPFGDAPRELRLRATRAFVAARSFVQGLGVGSDVVAKVAQVPLAPECSRAIMKLV 
rOCI  GARRD  ....  LKVFGSFFKLIMTQVSKSLQVTRIFLQALNLGIEVINTTDHLKFSKDCGRMLTRMW 
B2  GARRD--  LKVFGSFPKLIMTQVSKSLQVTRIFLQALNLGIEVINTTDHLKFSKDCGRMLARMW 
rCRB  RLTSTADGSLQPFGDSPRRLRLQITRALVAARALVQGLETGRNVVSEALKVPMLEGCRQALMRLI 
B 
hGLP  rGLP  B1  rOCI  B2  rCRB 
M2  44%  45%  44%  24%  24%  42% 
hGLP  91%  88%  20%  20%  40% 
rGLP  97%  20%  20%  40% 
B1  20%  20%  41% 
rOCI  98%  21% 
B2  21% 
Figure 1.  Deduced amino acid sequences of the cloned PCR frag- 
ments and their comparison with known members of the glypican 
family.  (A) Alignment of deduced amino acid sequences of the 
clone M2, B1, and B2 with corresponding regions of human glyp- 
ican (hGLP; David et al., 1990), rat glypican (rGLP; Karthikeyan 
et al., 1992), rat OCI-5 (rOCI; Filmus et al., 1988), and rat cere- 
broglycan (rCBR; Stipp et al., 1994). The first residue in M2, cor- 
responds to 6SSer in the complete K-glypican sequence (see Fig. 
2).  (B)  Percent  amino  acid  identities  between  the  sequences 
shown in A. Note that the comparisons were made only within 
the region shown above, since full-length  sequences for clone B1 
(mouse glypican) and B2 (mouse OCI-5) have not been deter- 
mined. When compared between full-length sequences, K-glypi- 
can is 43, 43, 21, and 38% identical to human glypican,  rat glypi- 
can, rat OCI-5, and rat cerebroglycan, respectively (see Results). 
sus  initiation  sequence  (Kozak,  1991),  and  terminates  at 
nucleotide 2153. No other ATG sites were found upstream 
of nucleotide  470.  The  overall  hydropathy profile  of the 
novel  glypican-like  molecule  is  similar  to  those  of  the 
other  members  of the  family, characterized  by the  pres- 
ence  of NHe-terminal  and  COOH-terminal  hydrophobic 
regions. The initiating  methionine  is followed by a  signal 
sequence of 21 amino acids (von Heijne, 1986). The COOH 
terminus of the putative protein contains a  13-residue hy- 
drophobic  stretch,  which  is  not  long  enough  to  form  a 
transmembrane  domain,  but  is  similar  to  the  signal  se- 
quence for GPI attachment present  in a  number of GPI- 
anchored proteins (Cross, 1990). According to the consen- 
sus for GPI attachment (Kodukula et al., 1993), we predict 
529Ser or 531Gly to be the  attachment  site  of the  GPI an- 
chor (Fig. 2). Excluding these NH2-terminal  and COOH- 
terminal signal sequences, which are presumably cleaved, 
the predicted molecular mass of the mature core protein is 
57.5 kD. An asparagine residue in the COOH-terminal re- 
gion at residue 514 represents  a potential N-glycosylation 
site.  Three serine-glycine dipeptide  sequences, which are 
thought to be potential glycosaminoglycan (GAG) attach- 
ment  sites,  are  present  as  a  cluster  at  residues  494-500, 
These serine-glycine dipeptides are surrounded  by acidic 
residues,  another  structural  feature  commonly found  in 
GAG attachment sites (Zimmermann and Ruoslahti, 1989). 
Alignment of the full-length sequence with other mem- 
bers of the glypican family for which full-length sequences 
have been determined showed that the novel glypican-like 
molecule is 43, 43, 21, and 38%  identical to human glypi- 
can, rat glypican, rat OCI-5, and rat cerebroglycan, respec- 
tively. The number and positions of cysteine residues  are 
almost completely conserved among all of these molecules 
(Fig. 3). The putative GAG attachment sites in the COOH- 
terminal  regions were also conserved, whereas additional 
putative NH2-terminal  GAG attachment sites are present 
only in glypican and cerebroglycan (Fig. 3). These results 
confirmed that the cloned cDNA represents a novel mem- 
ber of the glypican family, which we have named "K-glypi- 
can" based on the tissue origin of the cDNA. 
Protein Structure of K-Glypican 
To  determine  if  K-glypican  is  indeed  a  GPI-anchored 
HSPG, as predicted  from the  deduced primary structure, 
we transfected  MDCK  cells  with  K-glypican cDNA that 
had been tagged with the c-myc epitope, and analyzed the 
expressed K-glypican protein with anti--c-myc mAb (9El0). 
Two  MDCK  transfected  cell  clones  were  used:  clone 
K1B4, expressing K-glypican tagged at the COOH-termi- 
nal, and clone $2A3, expressing K-glypican tagged at the 
NH2-terminal  (Fig. 4 A). First,  GAG-degrading enzymes 
were  used  to  examine  whether  K-glypican  is  a  HSPG. 
When the PG fractions isolated from culture supernatants 
of  $2A3  cells  were  analyzed  by  Western  blotting  with 
9El0 mAb, a diffuse smear around ,~220 kD was detected 
(Fig. 4 B, lane 1). No band was detected in culture super- 
natants  of control  transfected  cells  (not  shown).  Treat- 
ment  with  a  mixture  of heparinases  I  and  III, which  de- 
grades  most  types  of heparan  sulfate  chains,  eliminated 
the smear and produced a 60-kD band (Fig. 4 B, lane 3). 
Treatment with chondroitinase ABC had no effect on the 
The Journal of Cell Biology, Volume 130,  1995  1210 AGC GGA CGA GCG CCG GGT GGC TGA AGC CCC GCG CCA CGA TCG CCC GCC GAC C-CC C,  CC CAC ACT CTG CTC TTC TGC GAC GCC TGC  CAC CTT  90 
CCC TTC CTT CCC TGA GCC CCT CCG CCC TGG CTA GCT GGC CCG GGT TCT CTA GCC TTC GGA GTC CCG AGG TCA CGG ATC CTC TCC CTA GTC  180 
CCT TC-G  GTC CCG CGC CCA TTC CAC GCC TTT TTC CTC GTA CCG CAC CCC GGC TGG GCG CCT GGC ACC GGG GAC CGT TGC CTG ACT CGA GGC  270 
CCA GCT CCA CTT TTC GCG CGC GTC TCC TCC TCC TGC CCT CCT CCT CCT CCT CCT CCT TCA CTA CCA ACT TCA ACT CCC CGG TTC TCG CTC  360 
C~  TCG TGA GTG TTC ACT CCG CGC CTC TCC C-CC CGC TCC GCA GCG CTG CTT TCC ATC GGG TCT CAT TCT GTC CCC TAA AGG TGG GAG C~  450 
.  A  T  A  A  24 
AAA TGC AGA GAA ATC CCT GAA TGA TAT GTT CGT GAA GAC ATA TGG CCA CTT ATA CAT ~A  AAA TTC AGA GCT ATT TAA AGA TCT CTT CGT  900 
N  A  E  K  S  L  N  D  M  F  V  K  T  Y  G  H  L  Y  M  Q  N  S  E  L  F  K  D  L  F  V  144 
TGA GTT GAA GCG CTA CTA TGT GGC C-C-G  AAA TGT GAA CCT GGA AOA AAT GTT AAA TGA CTT CTG GGC TCG CCT TCT GGA OCG CAT GTT TCG  990 
E  L  K  R  Y  Y  V  A  G  N  V  N  L  E  E  M  L  N  D  F  W  A  R  L  L  E  R  M  F  R  174 
L  N  S  Q  Y  H  F  T  D  E  Y  L  V  S  Y  T  E  Q  K  P  F  D  V  P  204 
TCG GAA ACT GAA C-CT CCA GGT TAC CCG CGC ATT TGT TGC AGC CA° GAC CTT CGC TCA AGG CTT AGC AGT TGC AAG GGA TGT AGT AAG CAA  1170 
R  K  L  K  L  Q  V  T  R  A  F  V  A  A  R  T  F  A  Q  G  L  A  V  A  R  D  V  V  S  K  234 
=  ccc cAe =  =  c  cA  ACT =  OAT OAT  =  CTC  =  coo  cot =  126o 
V  S  V  V  N  P  T  A  Q  ~  T  H  A  L  L  K  M  I  Y  ~  S  H  ~  R  G  L  V  T  V  K  264 
TAT C-CT GAT GGTGGC  AGA GAG GCTGGAGGGTCC  TTT CAACAT  TGA GTC CGT TAT GGA TCC CAT CGA TGT GAAGAT  TTC TGA TGCTAT  CAT  1440 
M  L  M  V  A  E  R  L  E  G  P  F  N  I  E  S  V  M  D  P  I  D  V  K  I  S  D  A  I  M  324 
G~  TATM  GCAQ  ~A  TNAA  TAGs  TGTv TCAQ  AGTv  °TCs ,CAQ  GAAK  C~vT  TTTF CCAQ  AGGG ~  TGGG CCCp TCCp °AAK  C~pC TCTL CCCp  AGCA TGGG  ACGR  ~T  TTCs TCGR  1530354 
CTC CAT CTC TGA AAG TGC CTT CAG TGC TCG ATT CAG ACC TTA ,CA TCC AGA GCA ACG CCC AAC CAC GGC AGC TGG CAC TAG TTT GGA CC°  1620 
S  I  S  E  S  A  F  S  A  R  F  R  P  Y  H  P  E  Q  R  P  T  T  A  A  G  T  S  L  D  R  384 
GGG CAA CAA CCC AGA AGT CCA GGT TGA CAC CAG CAA GCC AGA CAT ACT GAT CCT TCG ,CA °AT CAT GGC CCT TCG GG, TAT GAC CAG TAA  1890 
G  N  N  P  E  V  Q  V  D  T  S  K  P  D  I  L  I  L  R  Q  I  M  A  L  R  V  M  T  S  K  474 
•  GC AGA GAC AAA GCC CTA CCT CCT CGC TGC TCT C~G CAT CCT GTT TCT CGC TGT GCA GGG AGA °TG GAG ATA AT, GTC AAA CTC TGA GTA  2160 
A  E  T  K  P  Y  L  L  A  A  L  ~  I  L  F  L  A  V  Q  G  E  W  R  *  557 
AAA GCG TTC ATC ATC AGAAAG  TTC AAA GGC ACC AAG TTC TCA CTT TTT TTT TTT TTA ACC ATC CTA °TG ACT TTG CTT TTT AAA TGA ATG  2250 
GACAACAAT  GTA CAG TTT TTA CTG TGTGGCCAC  TGGTTTAAG  CAATGT  TGA CTT TGT TTTGCT  CAT ,CA GTTT~AGOGGAC  AGCGGGGCC  2340 
TCC TGC CTT TAA GTT TGT TCC TCC CCC TCA CCT CCC CCC TCC TTT GAG ACT CGT GTT CTG CGT GGC TAG CAG TQT AGG ,AC AGA ACT GTA  2430 
GTT AGT  TGT °CA TTG GTG ATC TTG TTT TCT TTG TTG ~T  TCT CTC ATT TTA TTT GTG GGG TTT TTC TTT TCC AAT TAT GG, CTC ACC TTG  2520 
TTT CTC ACA AGA AAA CCA GGG TCC TTT CTT GGC ATG TAA CAT GTA CGT AT, TCT GAA ATA TTA AAT AGC ,GT ACA GAA °CA GGT TTA TTT  2610 
ATC ATG TTA TCT TAT TAA AAG AAA AAG CCC AAA CAA GCT GGA AAA TTT CCA TTT ATC CCT GTT ATT TTA °CT GCC TTA TTG GGA GAG AAG  2700 
TGG AGT TGA CTT TGG GTT TTC TTC CTT TCT TTC TTT CTC TCT CT  2744 
Figure 2.  Nucleotide and deduced amino acid sequence of K-glypican. Complete amino acid sequence of K-glypican was deduced from 
nucleotide sequence of a full-length clone hMK6 (see text). Underlines indicate the hydrophobic stretches for the predicted signal se- 
quences for secretion (amino acid residues 1-22) and GPI-anchoring (residues 541-553). Predicted GPI-anchor attachment sites are in- 
dicated by triangles. Cysteine residues are circled. All serine-glycine dipeptides and an asparagine residue of a potential N-glyeosylation 
site are boxed. Double underlines indicate a potential RNA degradation signal (Shaw and Kamen, 1986; Malter, 1989). 
appearance  of the smear (Fig. 4 B, lane 2). Similar results 
were obtained when KIB4 cells were examined (Fig. 4  B, 
lanes  4  and 5).  These results indicate  that K-glypican  ex- 
pressed in these cells is a HSPG. 
To  demonstrate  that  K-glypican  is  anchored  to  cell 
membranes  by  a  GPI-linkage,  the  transfected  cell  lines 
were  treated  with  PI-PLC,  an  enzyme  that  specifically 
cleaves GPI-anchors  (Low,  1989).  Since it is possible that 
GPI-anchored  HSPGs  may  still  bind  to  cell  surfaces 
through heparan sulfate chains even after cleavage of GPI- 
anchors, cell suspensions were treated with 2 M NaC1 after 
digestion  with  PI-PLC  to  ensure  the  release  of  PI-PLC 
cleaved  K-glypican.  Most  of K-glypican  expressed  on the 
surface of $2A3 cells was released into supernatants by PI- 










oo  O  • 
~A-  RLGLLALLCTLAALSAS  L  -  -  LA-AELKSKSCSEVRRLYVSKGFNKNDA~LYEIN~DH~KIS-  ~QD  63 
MELRARGWWLLCAAAALVACA-  -  RGDPASKSRSCGEVRQIYGAKGFSLSDVPQAEI~HLRIC  -  pQe  65 
MELRARGWWLLCAAAALVACT  -  -  RGDPASKSRSCSEVRQIYGAKGFSLSDVPQAE  I~HLRI  C-  pQG  65 
MAGTVRTACLLVAMLLGLGCLGQAQPPPPPDATCHQVRSFFQRLQPGLKWVPETPVPGSDLQVCLPKG  68 
MSAVRP  LLLLLLPLCPGPGPG  -  -HGSEAKVVRSCAETRQVLGARGYSLNLI  PPSLI~EHLQIC-  pQE  65 
o~  •  •  •  •  • 
YTCCSQEMEEKYSLQSKDDFKTVVSEQCNHLQAIFASRYKKFDEFFKELLENAEKSLNDMFVKTYGHL  131 
YTCCTSEMEENLANRSHAELETALRDSSRVLQAMLATQLRS  FDDHFQHLLNDSERTLQATFPGAFGEL  133 
YTCCTSEMEENLANHSRMELETALHDS  SRALQATLATQLHGIDDHFQRLLNDSERTLQDAFPGAFGDL  133 
PTCC  SRKMEEKYQLTARLNMEQLLQSASMELKFL  I  IQNAAVFQEAFE IVVRHAKNYTNAMFKNNYP  S  L  136 
YTCC  S  SETEQKLIRDAEVTFRGLVE~SFLIHTLAARHRKFNEFFREMLS  I  SQHSLAQLFSHSYGRL  133 
mKGP  YMQNSELFKDLFVELKRYYVAGNVNLEEMLNDFWARLLERMFRLVNSQYHFTDEYLECVSKYTEQ---  196 
hGLP  YTQNARAFRDLYSELRLYYRGANLHLEETLAEFWARLLERLFKQLHPQLLLPDDYLDCLGKQAEA---  198 
rGLP  YTQNTRAFRDLYAELRLYYRGANLHLEETLAEFWARLLERLFKQLHPQLLLPDDYLDCLGKQAEA---  198 
rOCI  TPQAFEFVGEFFTDVSLYILGSDINVDDMVNELFDSLFPVIYTQMMNP-GLPESVLD-INECLRGARR  202 
rCBR  YSQHAVIFNSLF~LRDYYE~EGLDDTLADFWAQLLERAFPLLHPQYSFPPDFLLCLTRLTSTADG  201 
•  oo  •  •  •  •  •  0  0  0  • 
mKGP  -LKPFGDVPRKLKLQVTRAFVAARTFAQGLAVARDVVSKVSVVNPTAQCTHALLKMIYCSHCRGLVTV  263 
hGLP  -LRPFGEAPRELRLRATRAFVAARSFVQGLGVASDVVRKVAQVPLGPECSRAVMKLVYCAHCLGVPGA  265 
rGLP  -LRPFGDAPRELRLRATRAFVAARSFVQGLGVASDVVRKVAQVPLAPECSRAVMKLVYCAHCRGVPGA  265 
rOCI  DLKVFGAFPKLIMTQVSKSLQVTRIFLQALNLGIEVINTTDHLKFSKDCGRMLTRMWYCSYCQGLMMV  270 
rCBR  SLQPFGDSPRRLRLQITRALVAARALVQGLETGRNVVSEALKVPMLEGCRQALMRLIGCPLCRGVPSL  269 
eO  O  eO  •  •  •  • 
mKGP  KPCYNYCSNIMRGCLANQGDLDFEWNNFIDAMLMVAERLEGPFNIESVMDPIDVKISDAIMNMQDNSV  331 
hGLP  RPCPDYCRNVLKGCI~,NQ/~LDA~NRN~LDSM'VLITDKFNG~ESVIGSVH~II.~EAINALQDNRD  333 
rGLP  RPCPDYCRNVLKGCLANQADLDAEWRNLLDSMVLITDKFWGSP~EYVIGSVHMWLAEAINALQDNKD  333 
rOCI  KPCGGYCNVVMQGCMAGVVEIDKYWREYILSLEELVNGMYRIYDMENVLLGLFSTIHDSIQYVQKNGG  338 





















O  •  • 
QVSQKVFQGCGPPKPLPAGRISRSISESAFSAR--FRPYHPEQRPTTAAGTSLDRLVTDVKEKLKQAK  397 
TLTAKVIQGCGNPKVNPQGPGPEEKRRRG  ........  KLAPRERP~T---LEKLVSEAKAQLRDVQ  390 
TLTAKVIQGCGNPKVNPHG~PEEKRRRA  ........  KLALQEKSSTGT---LEKLVSEAKAQLRDIQ  390 
KLTTTIGKLCAHSQ  ........  QRQYRSAYYPEDLFIDKKVLKVARVEHEETLSSRRRELIQKLKSFI  398 
KVSAKVFQECGTPHPVQSRNRRAPAPREETSRS--WRSSAEEERPTTAAGTNLHRLVWELRERLSRVR  402 
Oe  O  Oe  •  eO  •  •  • 
KFWSSLPSTVCNDERMAAGNENED-DCWNGKG-KSRYLFAVTGNGLANQGNNPEVQVDTSKPDILILR  463 
DFWISLPGTLCS-EKMALSTASDD-RCWNGMA-RGRYLPEVMGDGLANQINNPEVEVDITKPDMTIRQ  455 
DYWISLPGTLCS-EKMAMSPASDD-RCWNGIS-KGRYLPEVWGDGLANQINNPEVEVDITKPDMTIRQ  455 
SFYSALPGYICSHSPV  ....  AENDTLCWNGQELVERYSQKAARNGMKNQFNLHELKMK--GPEPWSQ  460 
GFWAGLPVTVCGDSRMAADLSQEAAPCWTGVG-RGRYMSPVVVGSLNEQLHNPEL--DTSSPDVPTRR  467 
QIMA~RVMTSKMK--NAYN~NDV~--FFDISDES~E~EYQ--QCPSEFEYNATDH  .......  518 
QIMQLKIMTNRLR--SAYNGNDVD--FQDASDD~GCLDD--LCGRKVSRKSSSSRTPLTHA  517 
QIMQLKIMTNRLR--GAYGGNDVD--FQDASDDG~GISGBG~GCPDD--ACGRRVSKKSSSSRTPLIHA  517 
IIDKLKHINQLLRTMSVPKGKVVDKSLDEEGLE~DCGDDEDECIGS~DGMMKVKNQLRFLAELAYD  528 
RRLHLRAATARMK--AAALGQDLD--MHDADEDA~QQYADDWKAGAAPWPPARPPRPPRPPR  531 
-~KSANEKAD  ............ SAGGAHAETKPYLLAALCILFLAV-QGEWR  557 
LPGLSEQEGQK ............ TSAASCPQPPTFLLPLLLFLALTVARPRWR  558 
LPGLSEQEGQK ............ TSAATRPEPHYFFLLFLFTLVLAAARPRWR  558 
LDVDDAPGNKQHGNQKDNEITTSHSVGNMPSPLKILISVAIYVACFFSWCTDLPCPCLCCPAAPCGPPT  597 
RDGLGVRGG~SARYNQGRSRNLGSSVGLHAPRVFILLPSALTLL  .....  GLR  579 
Figure 3.  Alignment  of  the 
entire  primary sequences  of 
the members of the glypican 
family.  The  entire  primary 
sequence  of K-glypican was 
aligned with  the other mem- 
bers  of the  glypican  family 
for which entire primary se- 
quences have been published. 
mKGP,  mouse  K-glypican 
(this  paper);  hGLP,  human 
glypican (David et al., 1990); 
rGLP,  rat  glypican  (Kar- 
thikeyan et  al.,  1992); rOCI, 
rat  OCL5  (Filmus  et  al., 
1988); rCBR, rat cerebrogly- 
can (Stipp et al., 1994). Open 
and filled circles indicate cys- 
teine  and  other  amino  acid 
residues,  respectively,  which 
are  conserved  in  all  mem- 
bers.  Serine-glycine  dipep- 
tides that are potential GAG 
attachment sites are boxed. 
PLC treatment (Fig. 4 C). This result indicates that K-glyp- 
ican is anchored to the surface of these cells by a GPI-link- 
age. Small amounts of K-glypican were released during the 
incubation without PI-PLC (Fig. 4 C, lane 1), a phenome- 
non also observed with other GPI-anchored HSPGs  (see 
Discussion).  Similar  results  were  obtained  with  K1B4 
cells. No bands reactive with the anti-c-myc mAb were de- 
tected either in the PI-PLC-released or in the cell fraction 
of MDCK-neo control cells (not shown). 
Unexpectedly, these analyses revealed an apparent pro- 
teolytic cleavage site in the middle of the K-glypican core 
protein.  When the PG fraction of $2A3 ceils was isolated 
without  proteinase  inhibitors  and  then  immunoblotted 
with 9E10 mAb under reducing condition, a single 32-kD 
band was detected (Fig. 4 D, lane 3). In contrast, when the 
PG fraction was isolated in the presence of proteinase in- 
hibitors, a ~220-kD smear was detected (see Fig. 4, B and 
C).  Interestingly,  when  immunoblotting  was  performed 
under nonreducing condition, the 32-kD band was not de- 
tected; instead the smear as seen in the experiments with 
proteinase inhibitors was detected (Fig. 4 D, lane 1). In the 
case of K1B4 cells,  a  smear was detected  under both re- 
ducing and nonreducing conditions (Fig. 4 D, lanes 2  and 
4), though it migrated slightly faster under reducing condi- 
tion. These results suggest that there is a proteolytic cleav- 
age site in the middle of the K-glypican core protein and 
that  at  least  a  pair  of cysteine  residues  form a  disulfide 
linkage(s) bridging the NH2- and COOH-terminal sides of 
the cleavage site.  Although the physiological significance 
of the  cleavage is  unknown,  these  results  are  consistent 
with the suggestion that glypicans have tight tertiary struc- 
tures due to intramolecular  disulfide  bonds (David et al., 
1990; Stipp et al., 1994). 
Expression of K-Glypican mRNA 
To determine  the  tissue  distribution  and cellular  expres- 
sion  of the  K-glypican mRNA, a  series  of Northern  blot 
The Journal of Cell Biology, Volume 130, 1995  1212 Figure 4.  Characterization of K-glypican expressed in MDCK cells. A, Schematic presentation of the K-glypican constructs tagged with 
the human c-myc epitope. Meshed boxes represent hydrophobic stretches corresponding to the signal sequences. Potential GAG attach- 
ment sites and cysteine residues are vertical bars and dots, respectively. The positions of inserted c-myc epitope are shown by pentagons. 
(B) Treatment with GAG-degrading enzymes. The PG fractions isolated from $2A3 (lanes 1-3) and K1B4 (lanes 4 and 5) cells were 
treated with chondroitinase ABC (lanes 2 and 4) or a mixture of heparinases I and III (lanes 3 and 5). Epitope-tagged proteins were de- 
tected by Western blotting. (C) Treatment with PI-PLC. $2A3 cells were treated with (lanes 3 and 4) or without PI-PLC (lanes I  and 2). 
After the treatment, cells were centrifuged and the resulting supernatant (lanes 1 and 3) and cell fractions (lanes 2 and 4) were probed 
with 9E10 mAb in Western blotting. (D) Treatment with reducing reagents. The PG fractions from $2A3 cells (lanes I  and 3) and KIB4 
cells (lanes 2 and 4) were separated by SDS-PAGE under nonreducing (NR) or reducing conditions (R) and probed with 9E10 mAb in 
Western blotting. 
analyses was performed. A  3.4-kb K-glypican mRNA was 
detected in various adult mouse tissues, a thymic epithelial 
cell line, 2RO1.1, and an endothelial cell line, bEnd.4 (Fig. 
5  A).  Among the tissues examined, K-glypican is highly 
expressed in kidney, moderately in liver and lung, and at 
low levels in brain and spleen. 
We next analyzed the expression of glypican and OCI-5 
in  mouse tissues  and  cell lines  using  the PCR-amplified 
mouse glypican and OCI-5 probes. The mRNAs for mouse 
glypican and OCI-5 are 3.8 and 2.6 kb in size, respectively. 
The sizes are in good agreement with those of human glyp- 
ican (3.8 kb; David et al., 1990) and rat OCI-5 (2.6 kb; Fil- 
mus et al., 1988). Comparison of the expression of K-glyp- 
ican  with  those  of  glypican  and  OCI-5  demonstrated 
remarkable differences in their tissue distribution patterns 
(Fig. 5 A). Glypican is expressed in various mouse tissues 
at comparable levels, and is highly expressed in endothe- 
lial cell lines. The mRNA for mouse OCI-5 is most abun- 
dant in lung, but low levels of mRNA were detected in the 
brain, liver, and spleen. No OCI-5 expression was detected 
in any of the endothelial cell lines. 
As glypican and cerebroglycan have been implicated in 
the  development of the  nervous system  (Litwack  et  al., 
1994; Stipp et al., 1994), we investigated how the expres- 
sion of K-glypican is regulated in the developing brain. Be- 
cause  of  the  very  high  sequence  homologies  between 
mouse and rat (see Fig. 1 B), mouse cDNAs could be used 
to probe  mRNA  from rat brain.  As  shown in  Fig.  5  B, 
glypican, OCI-5, and K-glypican are expressed at compa- 
rable levels in the brain at embryonic day 17 (E17). Tem- 
poral expression patterns of these molecules, however, dif- 
fer  significantly.  Glypican  exhibits  a  constant  level  of 
expression at E17, postnatal day 2  (P2), and in the adult 
brain. In contrast, the expression of both K-glypican and 
OCI-5 decreases rapidly as the brain develops. K-glypican 
shows an earlier decrease in expression than  OCI-5, be- 
coming barely detectable at birth. 
In Situ Hybridization 
To map K-glypican expression in mouse embryo, in situ 
hybridization was performed. Fig. 6 shows the results of in 
situ hybridization with antisense and sense probes in adja- 
cent  sections  of an  E13  embryo. No  nonspecific signals 
were observed in  a  section hybridized with sense  probe 
(Fig. 6 B). In the section hybridized with antisense probe 
(Fig.  6 A), specific signals  for K-glypican expression are 
detected  in  a  variety of tissues  such  as  the  brain,  large 
blood vessels, and the developing adrenal gland (see be- 
low for detail). The expression in the kidney is not promi- 
nent at this stage. 
The expression of K-glypican in the kidney was exam- 
ined at several time points during development. At E13 in 
mice, the comma- and S-shaped pretubular epithelial ag- 
gregates that later give rise to the glomeruli and the proxi- 
mal and distal tubules are already formed (Kaufman, 1992; 
Gilbert,  1994).  Some  of  the  pretubular  aggregates  are 
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(top),  OCI-5  (middle),  and  K-glypican  (bottom)  mRNAs  in 
mouse tissues  and  cell lines.  Total RNA  (10  Ixg) from mouse 
brain (lane 1), kidney (lane 2), liver (lane 3), lung (lane 4), spleen 
(lane 5), and cell lines, 2ROl.1  (lane 6), sEnd.1  (lane  7), tEnd.1 
(lane  8),  bEnd.4  (lane  9),  and  eEnd.2  (lane  10)  were electro- 
phoresed,  transferred to  a  nylon  membrane, and  probed with 
mouse glypican  (clone B1),  OCI-5 (clone B2),  and  K-glypican 
(clone M2) cDNAs. The lower bands present in the lower panel 
(K-glypican) are nonspecific  hybridization  to the 18S ribosomal 
RNA. (B) Expression of glypican, OCI-5, and K-glypican mRNAs 
during brain development. Total RNA (10 Ixg)  from El7, P2, and 
adult rat brain were probed with glypican, OCI-5, and K-glypican 
cDNAs as described  above. 
found to express low levels of K-glypican at El3, though 
the majority of aggregates do not express K-glypican (Fig. 
7  A).  Soon  after the  formation  of the  S-shaped  bodies, 
cells in the  aggregates begin to differentiate into tubular 
epithelial cells as well as into capsule cells and podocytes 
in the glomeruli (Gilbert, 1994).  In El5 kidney, strong sig- 
nals for K-glypican mRNA are evident in  differentiating 
tubular epithelial cells (Fig. 7 B). There is a clear tendency 
for tubules that have formed a lumen to express K-glypi- 
can more strongly than those without a lumen. At El6 as 
the kidney develops further, the expression of K-glypican 
in  tubular  epithelial  cells  becomes  stronger  and  more 
widespread throughout the kidney (Fig. 7 C). In contrast, 
little  K-glypican  expression  is  observed  in  developing 
glomeruli (arrows). Fig. 7 A  also shows strong expression 
of K-glypican in the developing adrenal gland at El3. The 
expression  in  the  adrenal  gland  declines  appreciably  at 
El5 (Fig. 7 B) and is mostly lost at El6 (not shown). 
In  El3  embryo,  the  most  remarkable  expression  of 
K-glypican occurs in the  developing brain  (Fig. 6 A).  In- 
tense signals for K-glypican expression are detected in the 
areas surrounding the lateral ventricles of the telencepha- 
ion  (Fig.  8 A).  Expression of K-glypican is prominent in 
the lower half of the cerebral wall coinciding with radially 
aligned cells. The distribution of these positive signals ap- 
pears to correspond to  the  location  of proliferative neu- 
roepithelial cells in the ventricular zone, which occupies a 
large part of the cerebral wall at this stage (The Boulder 
Committee, 1970;  Sheppard et al.,  1991;  Kaufman, 1992). 
The outer layers of the cerebral wall are mostly devoid of 
the signal, except for a  narrow layer of cells beneath the 
pia. The expression of K-glypican is also found in the neu- 
roepithelium of the mesencephalic vesicle, the fourth ven- 
tricle, and the cerebellar primordium (Fig. 8 B). However, 
in  these  areas,  the  expression  of  K-glypican  is  much 
weaker than that in the  telencephalon,  and is largely re- 
stricted to a narrow layer adjacent to the ventricles. 
In El3 embryo, expression of K-glypican is observed in 
the ascending aorta (Fig. 8 C) and other large blood ves- 
sels  (see  Fig.  8  D).  Strong  labeling  appears  to  coincide 
with smooth muscle cells in the tunica media. Neither en- 
Figure 6.  In situ hybridization 
of  K-glypican  to  El3  mouse 
embryo,  Digoxigenin-labeled 
K-glypican RNA probes in an- 
tisense  (A) and sense  (B) ori- 
entation  were  hybridized  to 
adjacent  parasagittal  sections 
of an El3 mouse embryo. Ar- 
rows in A (from top to bottom) 
indicate  the  telencephalon, 
aorta,  and  adrenal  gland,  re- 
spectively. Bar, 1 mm. 
The Journal of Cell Biology,  Volume 130, 1995  1214 Figure  7.  Expression  of K-glypican  in  the  developing kidney. 
K-glypican mRNA was detected by in situ hybridization  with a 
digoxigenin-labeled  RNA  probe  in  antisense  orientation.  (A) 
Parasagittal  section of an E13 mouse embryo. A few pretubular 
aggregates express K-glypican. Strong expression of K-glypican is 
observed in the adrenal primordium. (B) Parasagittal section  of 
an E15 embryo. Strong expression  of K-glypican is observed in 
tubular epithelial  cells. K-glypican expression  in the adrenal de- 
clined significantly compared with the El3 embryo. (C) Parasag- 
ittal section of an E16 embryo. K-glypican-expressing  tubular ep- 
ithelial  cells  are widespread throughout  the kidney.  Note that 
little  expression  is  seen  in  glomeruli  (arrows). (Ad)  adrenal 
gland; (K) kidney. Bar, 200 ~m. 
dothelium  nor  tunica  adventitia  was  labeled  (Fig.  8  C). 
Less intense  but  significant  levels of K-glypican mRNA 
are also detected in the smooth muscle layer of intestines 
(Fig. 8 D). In contrast, no expression was detected in heart 
muscle  (Fig.  8  C).  Expression  of K-glypican is  also  ob- 
served  in  mesenchyme  of the  facial  area  and  hindlimbs 
(Fig. 6 A). 
Discussion 
Molecular Cloning of K-Glypican 
In this paper, we describe molecular cloning of a glypican- 
like molecule, named K-glypican. Several lines of evidence 
show that K-glypican is a  novel member of the  glypican 
family of proteoglycans. First, the deduced amino acid se- 
quence  of  K-glypican  is  only  21-43%  identical  to  pub- 
lished  sequences  for  glypican  and  OCI-5.  In  addition, 
mouse cDNAs for glypican and OCI-5 have been isolated 
as independent cDNAs distinct from K-glypican. Second, 
cerebroglycan, the only known family member we did not 
isolate a mouse cDNA for, is only 38% identical to K-glyp- 
ican.  That contrasts with the  high degree of interspecies 
conservation found in this family; for example mouse and 
rat glypicans are 97% identical. Thus, K-glypican does not 
appear to be a  mouse homologue of cerebroglycan. Fur- 
thermore,  the  results  of Northern  blot  analyses  showed 
that  the  developmental  expression  pattern  and  mRNA 
size  of K-glypican are  clearly distinct  from those  of the 
other three known members of the glypican family (Stipp 
et al., 1994; this study). Despite of the low levels of overall 
sequence homology, the predicted amino acid sequence of 
K-glypican contains  the  unique  features  that  all  known 
members  of  the  glypican  family  share.  Most  notably, 
K-glypican exhibits  almost complete conservation  in  the 
number and positions of the cysteine residues and contains 
a  cluster of serine-glycine sequences in the COOH-termi- 
nal  region  (Filmus  et  al.,  1988;  David  et  al,  1990;  Kar- 
thikeyan et al., 1992; Stipp et al., 1994).  From these obser- 
vations,  we  conclude  that  K-glypican  is  not  a  mouse 
homologue of any of these known members of the glypi- 
can family, but a novel member of the family. 
Our RT-PCR-based cloning approach failed to isolate 
the  mouse homologue of rat cerebroglycan. This may be 
due  to  sequence  difference  between  cerebroglycan  and 
glypican in the region of Primer 8 that was used for cDNA 
synthesis. The primer was designed based on a conserved 
tetrapeptide sequence, Cys-Trp-Asn-Gly, whereas the cor- 
responding  cerebroglycan  sequence  is  Cys-Trp-Thr-Gly 
(Stipp et al.,  1994).  Alternatively, the RNA sources used 
for  RT-PCR  may express  cerebroglycan mRNA  at  low 
levels. 
K-Glypican Is a GPI-anchored HSPG 
To confirm that K-glypican is a  GPI-anchored HSPG, we 
used  an  epitope-tagging method  (Kolodziej  and  Young, 
1991).  Experiments  using  GAG-degrading  enzymes and 
PI-PLC demonstrated  that  K-glypican is  indeed  a  GPI- 
anchored HSPG in transfected MDCK cells. The attach- 
ment of heparan sulfate chains is not likely to be an arti- 
fact  of  epitope  tagging,  because  the  epitope  sequence, 
EQKLISEEDL,  does  not  contain  any  of  the  consensus 
sequences  for GAG attachment.  In addition,  the  c-myc- 
tagged  proteoglycan,  betaglycan,  which  is  also  a  mem- 
brane-bound HSPG, has been reported to be as fully func- 
tional as the wild-type proteoglycan (L6pez-Casillas et al., 
1993). Therefore, the posttranslational modification of the 
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ican in the developing brain, 
blood vessels,  and intestines. 
K-glypican  mRNA  was 
detected by in situ hybridiza- 
tion  with  a  digoxigenin- 
labeled  RNA  probe  in  anti- 
sense  orientation.  (A)  The 
lateral  ventricle  of  El3 
mouse brain in a parasagittal 
section.  (Lv) lateral  ventri- 
cle, (Th) thalamus.  (B) Mes- 
encephalic  vesicle  and  the 
fourth ventricle of El3 brain 
in  a  parasagittal  section. 
(My) mesencephalic  vesicle, 
(IV)  fourth  ventricle,  (Cb) 
cerebellar  primordium.  (C) 
Aorta  and  heart  of an  El3 
mouse  embryo.  Strong  hy- 
bridization is seen in the wall 
of the aorta (Ao). No signal 
is detected in the endothelial 
layer or in heart muscle (H). 
(B) Intestines of an El3 em- 
bryo.  Moderate  hybridiza- 
tion is seen within the wall of 
the  intestines  (arrows).  A 
large  blood  vessel  with  a 
strong K-glypican signal is also 
seen  in  the  picture  (arrow- 
head). No signal is detected in 
the liver (L). Bars, 200/xm. 
c-myc-tagged K-glypican is  considered  to  reflect  that  of 
native K-glypican. Although we cannot rule out the possi- 
bility  that  K-glypican is present  as  a  nonproteoglycan or 
non-GPI-anchored form in vivo, our present  results  and 
the molecular similarities with glypican and cerebroglycan, 
both of which have been shown to present in tissues as GPI- 
anchored  HSPGs  (Herndon  and  Lander,  1990),  strongly 
suggest that K-glypican is also a  GPI-anchored HSPG  in 
vivo. 
We detected a significant amount of K-glypican released 
into culture supernatants  without treatment with PI-PLC. 
The occurrence of soluble forms have also been reported 
for human glypican in cultured fibrobtasts and endothelial 
cells (David et al.,  1990; Mertens et al., 1992), cerebrogly- 
can in rat brain (Stipp et al., 1994), and several other GPI- 
anchored proteins (e.g., Almqvist and Carlsson, 1988; Fur- 
ley et  al.,  1990; Hortsch  and  Goodman,  1990; Vestal  and 
Ranscht, 1992). It has been reported that a  GPI-anchored 
HSPG is released by endogenous GPI-specific phospholi- 
pase  D  present  in human bone marrow cells  (Brunner  et 
al.,  1994;  Metz  et  al.,  1994).  These  observations  suggest 
that  the  release  of the  glypican family HSPGs  may have 
some physiological significance. It is possible that the solu- 
ble forms of the glypican family HSPGs have biological ac- 
tivities which may differ from those of their GPI-anchored 
counterparts. 
Differential  Expression  of the Glypican Family HSPGs 
Comparison of the expression of the glypican family HSPGs 
has revealed a  highly divergent pattern  of tissue distribu- 
tion. For instance, while K-glypican mRNA is expressed in 
the  smooth muscle  layer of blood vessels  (see Fig.  8  C), 
glypican is  expressed  in human  aortic and umbilical  vein 
endothelial  cells  (Mertens  et  al.,  1992)  and  in mouse en- 
dothelial  cell lines  (this  study).  In developing intestines, 
K-glypican mRNA is present  in smooth muscle cells  (see 
Fig. 8 D), whereas OCI-5 has been detected in a rat intesti- 
nal  cell  line  representing  primitive  intestinal  epithelial 
cells (Filmus et al., 1988). These observations indicate that 
different  members  of  glypican  family  may  be  simulta- 
neously expressed in adjacent cell layers of a  single tissue 
in  vivo.  A  specific  set  of glypican  family  proteoglycans 
may be selected for expression depending on the cell type 
and its differentiation state. 
K-Glypican Expression  in Mouse Embryo 
To gain  an  initial  insight  into  the  location  of K-glypican 
expression,  we performed  in situ  hybridization on devel- 
oping mouse embryos. In the kidney, this revealed that the 
expression of K-glypican begins relatively late  during de- 
velopment when pretubular  aggregates start to differenti- 
ate. K-glypican continues to be expressed in differentiated 
tubular epithelium,  but little  expression is found in glom- 
eruli. 
HSPGs have been implicated in various aspects of kid- 
ney development.  In particular,  syndecan-1  is  thought to 
play a major role in the epithelial conversion of metaneph- 
rogenic mesenchyme  (Vainio  et  al.,  1989;  Gilbert,  1994). 
Syndecan-1  is  first  seen  around  undifferentiated  mesen- 
chymal  cells  surrounding  the  ureteric  bud  and  becomes 
strongly expressed in the pretubular aggregates and in the 
S-shaped bodies. Its expression then declines as the matu- 
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in glomeruli (Vainio et al., 1989). Thus spatiotemporal ex- 
pression patterns of syndecan-1 and K-glypican are clearly 
distinct. Thus, if K-glypican plays a developmental role in 
embryonic kidney, it would be distinct from that of synde- 
can-1  and is presumably  related  to the differentiation of 
tubular epithelial cells.  It has been shown that a heparin 
binding growth factor, hepatocyte growth factor,  has the 
ability to induce branching and tube formation by kidney 
epithelial cells  in vitro  (Montesano  et al., 1991a,  b), and 
that  this  activity  is  modulated  by  heparan  sulfate  pro- 
teoglycans (Santos and Nigam,  1993). K-glypican may be 
involved  in  tubular morphogenesis  through this  type  of 
modulation  of  growth  factor  activities.  Moreover,  since 
K-glypican is highly expressed in the adult kidney, it may 
also have a physiological function in the mature organ. In 
this context, it is interesting to note that protein C inhibi- 
tor,  a  member  of the  serine  protease  inhibitor  (serpin) 
family  that  is  present  in  various  body  fluids  including 
urine, is bound to the apical surface  of kidney epithelial 
cells through cell surface heparan sulfate (Priglinger et al., 
1994). If K-glypican is actually sorted to the apical surface 
of epithelial  cells  as  predicted  from  its  GPI-anchor,  this 
HSPG may be the key component that acts to retain pro- 
tein C inhibitor on the luminal surface of the urinary tract. 
Recent studies, including those in this paper, have dem- 
onstrated that embryonic brain is one of the most promi- 
nent sites of the expression of the glypican family HSPGs. 
All four known members  of the family are  expressed  in 
the brain during development. Among them, only glypican 
is expressed both in embryonic and adult brain at compa- 
rable  levels.  On the other hand, K-glypican,  cerebrogly- 
can, and OCI-5 are expressed predominantly in embryonic 
brain, and their expression declines as the brain develops 
(Stipp et al., 1994; this study). However, our in situ hybrid- 
ization results show that the regulation of expression ap- 
pears to be much more intricate than this simple picture. 
Although K-glypican and cerebroglycan show similar ex- 
pression patterns in Northern blotting experiments, there 
are remarkable differences in their spatial expression pat- 
terns. Stipp et al.  (1994)  reported that, while cerebrogly- 
can is widely expressed in the nervous system, little if any 
cerebroglycan  mRNA  is  found  in  the  proliferative  neu- 
roepithelial cells in the ventricular zone. Such an expres- 
sion  pattern  is  clearly  distinct  from  that  of  K-glypican, 
which is predominantly expressed in the ventricular zone. 
Thus, the present study strongly suggests that the expres- 
sion of these  two HSPGs  is  differentially  regulated  in a 
highly stringent manner  during cortical  development.  A 
more detailed study in which the expression of both K-glyp- 
ican and cerebroglycan is examined in parallel will estab- 
lish the correlation between  the  differentiation  states  of 
neuroepithelial  cells  and the expression  of these HSPGs 
during  cortical  development.  Moreover,  future  studies 
should  address  whether  K-glypican  is  functionally  in- 
volved in the proliferation of neuroepithelial cells, as hep- 
arin binding growth factors  and HSPG  have been impli- 
cated  in this process  (Gonzalez et al., 1990; Bloch et al., 
1992; Nurcombe et al., 1993; Baird, 1994). 
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